Articles by tag: ophthalmology

FDA approved the first ophthalmic bevacizumab LYTENAVA for the treatment of wet AMD

FDA accepted Outlook Therapeutics' appeal and will approve LYTENAVA — a standardized bevacizumab for neovascular AMD. Analysis of consequences for the anti-VEGF market, pricing, and patients. Read more.

Targeted therapy for Usher syndrome 1B: new data on AAVB-081

Interim data from phase 1/2 gene therapy AAVB-081 for Usher syndrome 1B: safety, efficacy, and prognosis. Learn about the dual AAV vector and treatment prospects.